Letter from the Editor

Dear Readers,

Thank you for choosing our Medicom Conference Report of the 2022 American College of Cardiology Scientific Session that took place in Washington D.C. This year’s meeting was invigorating with a hybrid of in-person and remote attendees. The program was rich in innovative science, late-breaking studies, and engaging virtual content.

In the following pages you will find late-breaking science on optimal management of patients undergoing non-cardiac surgery from POISE-3, new coronary plaque data for alirocumab, surprise outcome for sodium restriction in heart failure, exciting findings for Lp(a) reduction from APOLLO, and promising data on the safety of Factor XI inhibition in AF from the PACIFIC program.

We hope you find our peer-reviewed summaries informative, engaging, and balanced. Most of all, we wish you all a safe and healthy 2022 and hope that this year brings our scientific community even closer together.

Sincerely,

Marc

 



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi



Posted on 15 June 202221 June 2022